Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
- Market Cap ₹ 7.24 Cr.
- Current Price ₹ 1.81
- High / Low ₹ 2.72 / 1.74
- Stock P/E 19.0
- Book Value ₹ 1.10
- Dividend Yield 0.00 %
- ROCE 7.27 %
- ROE 9.03 %
- Face Value ₹ 1.00
Pros
- Debtor days have improved from 408 to 34.7 days.
Cons
- Promoter holding is low: 20.0%
- Company has a low return on equity of 0.00% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -27.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 3 | 6 | 2 | 9 | 9 | 9 | 14 | 14 | 3 | 112 | |
| 0 | 0 | 4 | 6 | 2 | 10 | 9 | 9 | 13 | 14 | 3 | 112 | |
| Operating Profit | -0 | -0 | -0 | 1 | -0 | -0 | 0 | 0 | 1 | 1 | -0 | 1 |
| OPM % | -5% | 10% | -1% | -3% | 1% | 1% | 5% | 6% | -12% | 1% | ||
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 0 | -1 | 1 |
| Tax % | 0% | 0% | 0% | 11% | 0% | 0% | 33% | 0% | 17% | 26% | 0% | 27% |
| -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 0 | -1 | 0 | |
| EPS in Rs | -0.01 | -0.32 | -0.04 | 0.06 | -0.11 | -0.05 | 0.02 | 0.12 | 0.14 | 0.08 | -0.18 | 0.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 65% |
| 3 Years: | 99% |
| TTM: | 3757% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 31% |
| 3 Years: | -13% |
| TTM: | 154% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -25% |
| 3 Years: | -48% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 5% |
| 3 Years: | 0% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 0.19 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | -4 | -0 | -0 | -0 | -1 | -1 | -1 | -0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 1 | 1 | 1 | 0 | 0 | 4 | 7 | 3 | 6 | 8 | |
| 0 | 0 | 3 | 5 | 6 | 9 | 4 | 6 | 9 | 9 | 4 | 6 | |
| Total Liabilities | 1 | 1 | 7 | 10 | 11 | 12 | 8 | 14 | 20 | 17 | 14 | 18 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 1 | 1 | 5 | 8 | 9 | 10 | 6 | 12 | 19 | 15 | 12 | 16 | |
| Total Assets | 1 | 1 | 7 | 10 | 11 | 12 | 8 | 14 | 20 | 17 | 14 | 18 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -2 | -0 | 1 | 3 | -3 | -1 | 0 | 2 | -2 | -1 | |
| 0 | 0 | 2 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | |
| 0 | 0 | -2 | -1 | -1 | -3 | 3 | 1 | -0 | -2 | 2 | 1 | |
| Net Cash Flow | 0 | -0 | -2 | -1 | -0 | 0 | -0 | -0 | 0 | -0 | -0 | -0 |
| Free Cash Flow | -0 | -0 | -2 | -0 | 1 | 3 | -3 | -1 | 0 | 2 | -2 | -1 |
| CFO/OP | 80% | 83% | 1,165% | -25% | -4,567% | -966% | -2,331% | -971% | 38% | 236% | 686% | -151% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 267 | 287 | 911 | 250 | 242 | 294 | 313 | 263 | 927 | 35 | ||
| Inventory Days | 215 | 150 | 352 | 34 | 17 | 96 | 45 | 51 | 255 | 10 | ||
| Days Payable | 304 | 319 | 1,060 | 325 | 164 | 236 | 244 | 231 | 447 | 20 | ||
| Cash Conversion Cycle | 178 | 118 | 203 | -41 | 95 | 154 | 114 | 82 | 735 | 24 | ||
| Working Capital Days | 369 | 251 | 656 | 139 | 156 | 52 | 46 | 73 | 277 | 9 | ||
| ROCE % | -8% | -10% | -5% | 14% | -1% | 6% | 18% | 15% | 12% | 9% | -4% | 7% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees absolute |
|
||||||||||
| Trade Receivables Turnover Ratio (Standalone) times |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 May - As per Regulation 47 of the SEBI (LODR) Regulations, 2015, Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and …
-
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended On 31St March, 2026
7 May - Board approved FY26 audited results; noted director and company secretary resignations, and committee reconstitution.
-
Results- Quarterly And Year To End Dated 31St March 2026
7 May - Board approved audited FY26 results and noted director, company secretary resignations; committees reconstituted on 7 May 2026.
-
Non Applicability Of Related Party Transaction Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015 For The Quarter And Year Ended 31St March, 2026
7 May - Regulation 23(9) disclosure not applicable for quarter and year ended 31 March 2026.
-
Board Meeting Intimation for Rescheduling Of Board Meeting-Intimation Under Regulation 29 Of SEBI (LODR) Regulations, 2015.
4 May - Board meeting rescheduled to May 7, 2026 to approve FY26 audited results; trading window remains closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products